Inpefa
Total Payments
$2.3M
Transactions
18,951
Doctors
9,793
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.7M | 3,666 | 1,888 |
| 2023 | $647,382 | 15,285 | 8,501 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $1.4M | 517 | 62.9% |
| Food and Beverage | $539,605 | 17,484 | 23.4% |
| Travel and Lodging | $190,798 | 924 | 8.3% |
| Consulting Fee | $99,930 | 20 | 4.3% |
| Unspecified | $15,764 | 2 | 0.7% |
| Space rental or facility fees (teaching hospital only) | $5,000 | 1 | 0.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,213 | 2 | 0.1% |
| Grant | $1,200 | 1 | 0.1% |
Payments by Type
General
$2.3M
18,949 transactions
Research
$15,764
2 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Effects of Sotagliflozin in regulation of clotting and thrombotic Risk | Lexicon Pharmaceuticals, Inc. | $11,164 | 0 |
| LX9211.1-204-DPN-A Phase 2b, Dose-ranging, Randomized, Double-blind, Placebo-controlled, Parallel-Group, Multicenter Study with an Open0label Extension in Patients with Diabetic Peripheral Neurophathic Pain. | Lexicon Pharmaceuticals, Inc. | $4,600 | 0 |
Top Doctors Receiving Payments for Inpefa
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Cardiovascular Disease | Scottsdale, AZ | $75,428 | 71 |
| , M.D | Internal Medicine | Houston, TX | $58,677 | 87 |
| , M.D | Cardiovascular Disease | New Haven, CT | $57,355 | 57 |
| , MD | Internal Medicine | Vero Beach, FL | $56,690 | 64 |
| , MD | Cardiovascular Disease | Mission Hills, CA | $53,907 | 75 |
| , M.D | Specialist | Beverly Hills, CA | $51,737 | 52 |
| , MD | Cardiovascular Disease | Los Angeles, CA | $50,437 | 66 |
| , M.D | Cardiovascular Disease | Saint Louis, MO | $48,745 | 48 |
| , MD | Cardiovascular Disease | Mobile, AL | $48,565 | 59 |
| , M.D | Cardiovascular Disease | Columbus, GA | $47,671 | 46 |
| , M.D | Internal Medicine | Houston, TX | $46,786 | 67 |
| , MBBCHBAO | Cardiovascular Disease | Salt Lake City, UT | $44,819 | 50 |
| , M.D | Clinical Cardiac Electrophysiology | Dallas, TX | $43,109 | 65 |
| , MD | Cardiovascular Disease | Philadelphia, PA | $42,491 | 32 |
| , MD | Cardiovascular Disease | Hyannis, MA | $41,273 | 47 |
| , M.D | Cardiovascular Disease | Santa Monica, CA | $39,172 | 57 |
| , MD | Interventional Cardiology | Gainesville, FL | $38,837 | 42 |
| , MD | Cardiovascular Disease | Pgh, PA | $37,332 | 57 |
| , DO | Interventional Cardiology | Roslyn, NY | $36,488 | 33 |
| , D.O | Internal Medicine | Rochester, NY | $33,383 | 40 |
| , M.D, MSC | Advanced Heart Failure and Transplant Cardiology | New York, NY | $32,143 | 48 |
| , MD | Cardiovascular Disease | Cincinnati, OH | $31,872 | 30 |
| , M.D | Interventional Cardiology | Bloomfield Hills, MI | $31,079 | 39 |
| , DO | Cardiovascular Disease | Fayetteville, GA | $30,479 | 41 |
| , M.D | Student in an Organized Health Care Education/Training Program | Durham, NC | $30,170 | 27 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $2.3M
- Total Doctors 9,793
- Transactions 18,951
About Inpefa
Inpefa is a drug associated with $2.3M in payments to 9,793 healthcare providers, recorded across 18,951 transactions in the CMS Open Payments database. The primary manufacturer is Lexicon Pharmaceuticals, Inc..
Payment data is available from 2023 to 2024. In 2024, $1.7M was paid across 3,666 transactions to 1,888 doctors.
The most common payment nature for Inpefa is "Honoraria" ($1.4M, 62.9% of total).
Inpefa is associated with 2 research studies, including "Effects of Sotagliflozin in regulation of clotting and thrombotic Risk" ($11,164).